Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY

v3.22.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated deficit
Balance as of beginning of period (in shares) at Dec. 31, 2019   108,838,000    
Balance as of beginning of period at Dec. 31, 2019 $ (55,868) $ 11 $ 202,796 $ (258,675)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Exchange of related party convertible debt to common shares (in shares)   41,259,000    
Exchange of related party convertible debt to common shares 207,782 $ 4 207,778  
Exchange of convertible debt to common shares (in shares)   21,960,000    
Exchange of convertible debt to common shares 86,757 $ 2 86,755 0
Issuance of shares for restricted stock units vested (in shares)   101,000    
Issuance costs 22,508      
Issuance of shares upon exercise of share options (in shares)   424,000    
Settlement of offering costs 0      
Shares issued in offering, net of issuance costs (in shares)   69,549,000    
Shares issued in offering, net of issuance costs of $22,508 607,136 $ 7 607,129  
Offering costs (19,088)   (19,088)  
Repurchase of unvested shares - forfeitures (in shares)   (6,378,000)    
Stock-based compensation 84,280   84,280  
Settlement on restricted stock tax withholding (448)   (448)  
Private placements warrant liability (9,745)   (9,745)  
Contingent earnout shares liability (248,878)   (248,878)  
Conversion of private placement warrants to public warrants 0      
Net loss and comprehensive loss (86,686)     (86,686)
Balance as of end of period (in shares) at Dec. 31, 2020   235,753,000    
Balance as of end of period at Dec. 31, 2020 $ 565,242 $ 24 910,579 (345,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Proceeds from exercise of public warrants (in shares) 598,275 598,000    
Proceeds from exercise of public warrants $ 6,880   6,880  
Issuance of shares for restricted stock units vested (in shares)   3,684,000    
Issuance of shares for restricted stock units vested $ 0   0  
Issuance of shares upon exercise of share options (in shares) 70,396 70,000    
Issuance of shares upon exercise of vested stock options $ 1   1  
Vesting of early exercised stock options and restricted stock awards 49   49  
Settlement of offering costs 2,000   2,000  
Repurchase of unvested shares - forfeitures (in shares)   (1,527,000)    
Repurchase of unvested shares – forfeitures (17)   (17)  
Stock-based compensation 108,360   108,360  
Private placements warrant liability 0      
Conversion of private placement warrants to public warrants 8,252   8,252  
Net loss and comprehensive loss (346,768)     (346,768)
Balance as of end of period (in shares) at Dec. 31, 2021   238,578,000    
Balance as of end of period at Dec. 31, 2021 $ 343,999 $ 24 $ 1,036,104 $ (692,129)